Sanofi builds $75 mn factory in Vietnam for ASEAN markets

French drugmaker Sanofi said Friday that it had begun building a new manufacturing facility in Vietnam to serve the expanding pharmaceutical market in southeast Asia.

The $75 million (58 million euro) factory "will expand Sanofi's manufacturing capacity in Vietnam to meet the fast growing demand of the Vietnamese and will serve as an export platform to ASEAN countries," the company said in a statement.

The factory in Ho Chi Minh City, Sanofi's second, is due to be completed in 2015 with an initial capacity of 90 million units per year.

also boasts factories in Indonesia, Singapore and Thailand in the 10-country Association of Southeast Asian Nations (ASEAN), a market of some 600 million people.

lgo/rl/yad

add to favorites email to friend print save as pdf

Related Stories

US solar firm to build $300 mln Vietnam plant

Jan 26, 2011

A US solar panel maker Wednesday said it will build a $300 million factory in Vietnam, boosting the country's efforts to reinvent itself as a hub for high-tech manufacturing.

Recommended for you

Determine patient preferences by means of conjoint analysis

23 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments